View Financial HealthCellid 배당 및 자사주 매입배당 기준 점검 0/6Cellid 배당금을 지급한 기록이 없습니다.핵심 정보n/a배당 수익률n/a자사주 매입 수익률총 주주 수익률n/a미래 배당 수익률n/a배당 성장률n/a다음 배당 지급일n/a배당락일n/a주당 배당금n/a배당 성향n/a최근 배당 및 자사주 매입 업데이트업데이트 없음모든 업데이트 보기Recent updates공시 • Mar 07Cellid, Co., Ltd., Annual General Meeting, Mar 31, 2026Cellid, Co., Ltd., Annual General Meeting, Mar 31, 2026, at 10:00 Tokyo Standard Time. Location: conference room, 1, gwanak-ro, gwanak-gu, seoul South KoreaNew Risk • Jan 28New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 10% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks No financial data reported. Shareholders have been substantially diluted in the past year (40% increase in shares outstanding). Minor Risks Share price has been volatile over the past 3 months (10% average weekly change). Market cap is less than US$100m (₩101.2b market cap, or US$70.7m).공시 • Jun 18Cellid, Co., Ltd. has completed a Follow-on Equity Offering in the amount of KRW 35.784 billion.Cellid, Co., Ltd. has completed a Follow-on Equity Offering in the amount of KRW 35.784 billion. Security Name: Common Stock Security Type: Common Stock Securities Offered: 8,400,000 Price\Range: KRW 4260 Discount Per Security: KRW 76.68 Transaction Features: Rights OfferingNew Risk • May 07New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 8.9% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks No financial data reported. Shareholders have been substantially diluted in the past year (55% increase in shares outstanding). Minor Risks Share price has been volatile over the past 3 months (8.9% average weekly change). Market cap is less than US$100m (₩84.0b market cap, or US$60.0m).New Risk • Apr 23New major risk - Financial data availabilityThe company has not reported any financial data. This is considered a major risk. With no or incomplete audited reported financial data, it is virtually impossible to assess the company's investment potential. Currently, the following risks have been identified for the company: Major Risks No financial data reported. Shareholders have been substantially diluted in the past year (55% increase in shares outstanding). Minor Risk Market cap is less than US$100m (₩78.5b market cap, or US$55.1m).공시 • Mar 19Cellid, Co., Ltd. has filed a Follow-on Equity Offering in the amount of KRW 24.15 billion.Cellid, Co., Ltd. has filed a Follow-on Equity Offering in the amount of KRW 24.15 billion. Security Name: Common Stock Security Type: Common Stock Securities Offered: 8,400,000 Price\Range: KRW 2875 Transaction Features: Rights Offering공시 • Feb 27Cellid, Co., Ltd., Annual General Meeting, Mar 26, 2025Cellid, Co., Ltd., Annual General Meeting, Mar 26, 2025, at 10:00 Tokyo Standard Time. Location: conference room, 1, gwanak-ro, gwanak-gu, seoul South Korea분석 기사 • Dec 10Is Cellid (KOSDAQ:299660) Weighed On By Its Debt Load?The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...New Risk • Nov 28New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -₩25b This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₩25b free cash flow). Share price has been highly volatile over the past 3 months (20% average weekly change). Earnings have declined by 25% per year over the past 5 years. Shareholders have been substantially diluted in the past year (55% increase in shares outstanding). Minor Risks Revenue is less than US$5m (₩2.3b revenue, or US$1.6m). Market cap is less than US$100m (₩120.1b market cap, or US$86.1m).New Risk • Aug 23New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 117% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (27% average weekly change). Earnings have declined by 30% per year over the past 5 years. Shareholders have been substantially diluted in the past year (117% increase in shares outstanding). Revenue is less than US$1m (₩914m revenue, or US$684k).공시 • Aug 08Cellid, Co., Ltd. has completed a Follow-on Equity Offering in the amount of KRW 23.175 billion.Cellid, Co., Ltd. has completed a Follow-on Equity Offering in the amount of KRW 23.175 billion. Security Name: Common Stock Security Type: Common Stock Securities Offered: 6,422,072 Price\Range: KRW 3090 Discount Per Security: KRW 49.44 Security Name: Common Stock Security Type: Common Stock Securities Offered: 1,077,928 Price\Range: KRW 3090 Discount Per Security: KRW 49.44 Transaction Features: Rights OfferingNew Risk • Jul 23New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of South Korean stocks, typically moving 12% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (12% average weekly change). Earnings have declined by 34% per year over the past 5 years. Revenue is less than US$1m. Minor Risks Shareholders have been diluted in the past year (40% increase in shares outstanding). Market cap is less than US$100m (₩31.1b market cap, or US$22.4m).New Risk • May 27New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 8.3% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₩18b free cash flow). Earnings have declined by 34% per year over the past 5 years. Revenue is less than US$1m. Minor Risks Share price has been volatile over the past 3 months (8.3% average weekly change). Shareholders have been diluted in the past year (40% increase in shares outstanding). Market cap is less than US$100m (₩39.4b market cap, or US$29.0m).분석 기사 • Feb 28Is Cellid (KOSDAQ:299660) Using Debt In A Risky Way?Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...New Risk • Sep 26New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 40% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₩11b free cash flow). Earnings have declined by 44% per year over the past 5 years. Revenue is less than US$1m (₩480m revenue, or US$356k). Minor Risks Share price has been volatile over the past 3 months (10% average weekly change). Shareholders have been diluted in the past year (40% increase in shares outstanding). Market cap is less than US$100m (₩57.6b market cap, or US$42.8m).New Risk • Jun 20New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 8.2% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₩11b free cash flow). Earnings have declined by 34% per year over the past 5 years. Revenue is less than US$1m (₩480m revenue, or US$373k). Minor Risks Share price has been volatile over the past 3 months (8.2% average weekly change). Market cap is less than US$100m (₩64.2b market cap, or US$49.9m).Board Change • Nov 16No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 8 experienced directors. No highly experienced directors. No independent directors (8 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.공시 • Mar 21Cellid, Co., Ltd. announced that it has received KRW 19 billion in fundingOn March 19, 2021, Cellid, Co., Ltd. (KOSDAQ:A299660) closed the transaction.공시 • Mar 19Cellid, Co., Ltd. announced that it expects to receive KRW 19 billion in fundingCellid, Co., Ltd. (KOSDAQ:A299660) announced a private placement of 2nd series unregistered non-guaranteed private equity convertible bonds for gross proceeds of KRW 19,000,000,000 on March 17, 2021. The transaction will include participation from Daily Bio Health Care 1 Startup Venture Private Equity Joint Venture. The bonds will carry a zero coupon rate and zero yield to maturity. The bonds will mature on March 19, 2026. The bonds will be fully convertible into 515,296 shares of the company at a price of KRW 36,872 per share between the period of March 19, 2022 to February 19, 2026. The transaction has been approved by the board of directors of the company. The expected payment date and subscription date is March 19, 2021.분석 기사 • Mar 04Is Cellid (KOSDAQ:299660) In A Good Position To Invest In Growth?Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...공시 • Feb 25Cellid, Co., Ltd., Annual General Meeting, Mar 24, 2021Cellid, Co., Ltd., Annual General Meeting, Mar 24, 2021, at 10:00 Korea Standard Time.Is New 90 Day High Low • Jan 13New 90-day low: ₩37,650The company is down 24% from its price of ₩49,250 on 15 October 2020. The South Korean market is up 29% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is up 23% over the same period.분석 기사 • Nov 19Cellid (KOSDAQ:299660) Is In A Good Position To Deliver On Growth PlansThere's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...Is New 90 Day High Low • Oct 05New 90-day high: ₩50,700The company is up 81% from its price of ₩28,050 on 07 July 2020. The South Korean market is up 8.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is up 5.0% over the same period.지급의 안정성과 성장배당 데이터 가져오는 중안정적인 배당: 과거에 A299660 의 주당 배당금이 안정적이었는지 판단하기에는 데이터가 부족합니다.배당금 증가: A299660 의 배당금 지급이 증가했는지 판단하기에는 데이터가 부족합니다.배당 수익률 vs 시장Cellid 배당 수익률 vs 시장A299660의 배당 수익률은 시장과 어떻게 비교되나요?구분배당 수익률회사 (A299660)n/a시장 하위 25% (KR)1.0%시장 상위 25% (KR)3.7%업계 평균 (Biotechs)0.5%분석가 예측 (A299660) (최대 3년)n/a주목할만한 배당금: 회사가 최근 지급을 보고하지 않았기 때문에 하위 25%의 배당금 지급자에 대해 A299660 의 배당 수익률을 평가할 수 없습니다.고배당: 회사가 최근 지급을 보고하지 않았기 때문에 배당금 지급자의 상위 25%에 대해 A299660 의 배당 수익률을 평가할 수 없습니다.주주 대상 이익 배당수익 보장: 배당금 지급이 수익으로 충당되는지 확인하기 위해 A299660 의 지급 비율을 계산하기에는 데이터가 부족합니다.주주 현금 배당현금 흐름 범위: A299660 에서 지급을 보고하지 않았기 때문에 배당 지속 가능성을 계산할 수 없습니다.높은 배당을 제공하는 우량 기업 찾기7D1Y7D1Y7D1YKR 시장에서 배당이 강한 기업.View Management기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/05/22 05:18종가2026/05/22 00:00수익N/A연간 수익N/A데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Cellid, Co., Ltd.는 0명의 분석가가 다루고 있습니다. 이 중 0명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
공시 • Mar 07Cellid, Co., Ltd., Annual General Meeting, Mar 31, 2026Cellid, Co., Ltd., Annual General Meeting, Mar 31, 2026, at 10:00 Tokyo Standard Time. Location: conference room, 1, gwanak-ro, gwanak-gu, seoul South Korea
New Risk • Jan 28New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 10% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks No financial data reported. Shareholders have been substantially diluted in the past year (40% increase in shares outstanding). Minor Risks Share price has been volatile over the past 3 months (10% average weekly change). Market cap is less than US$100m (₩101.2b market cap, or US$70.7m).
공시 • Jun 18Cellid, Co., Ltd. has completed a Follow-on Equity Offering in the amount of KRW 35.784 billion.Cellid, Co., Ltd. has completed a Follow-on Equity Offering in the amount of KRW 35.784 billion. Security Name: Common Stock Security Type: Common Stock Securities Offered: 8,400,000 Price\Range: KRW 4260 Discount Per Security: KRW 76.68 Transaction Features: Rights Offering
New Risk • May 07New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 8.9% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks No financial data reported. Shareholders have been substantially diluted in the past year (55% increase in shares outstanding). Minor Risks Share price has been volatile over the past 3 months (8.9% average weekly change). Market cap is less than US$100m (₩84.0b market cap, or US$60.0m).
New Risk • Apr 23New major risk - Financial data availabilityThe company has not reported any financial data. This is considered a major risk. With no or incomplete audited reported financial data, it is virtually impossible to assess the company's investment potential. Currently, the following risks have been identified for the company: Major Risks No financial data reported. Shareholders have been substantially diluted in the past year (55% increase in shares outstanding). Minor Risk Market cap is less than US$100m (₩78.5b market cap, or US$55.1m).
공시 • Mar 19Cellid, Co., Ltd. has filed a Follow-on Equity Offering in the amount of KRW 24.15 billion.Cellid, Co., Ltd. has filed a Follow-on Equity Offering in the amount of KRW 24.15 billion. Security Name: Common Stock Security Type: Common Stock Securities Offered: 8,400,000 Price\Range: KRW 2875 Transaction Features: Rights Offering
공시 • Feb 27Cellid, Co., Ltd., Annual General Meeting, Mar 26, 2025Cellid, Co., Ltd., Annual General Meeting, Mar 26, 2025, at 10:00 Tokyo Standard Time. Location: conference room, 1, gwanak-ro, gwanak-gu, seoul South Korea
분석 기사 • Dec 10Is Cellid (KOSDAQ:299660) Weighed On By Its Debt Load?The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...
New Risk • Nov 28New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -₩25b This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₩25b free cash flow). Share price has been highly volatile over the past 3 months (20% average weekly change). Earnings have declined by 25% per year over the past 5 years. Shareholders have been substantially diluted in the past year (55% increase in shares outstanding). Minor Risks Revenue is less than US$5m (₩2.3b revenue, or US$1.6m). Market cap is less than US$100m (₩120.1b market cap, or US$86.1m).
New Risk • Aug 23New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 117% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (27% average weekly change). Earnings have declined by 30% per year over the past 5 years. Shareholders have been substantially diluted in the past year (117% increase in shares outstanding). Revenue is less than US$1m (₩914m revenue, or US$684k).
공시 • Aug 08Cellid, Co., Ltd. has completed a Follow-on Equity Offering in the amount of KRW 23.175 billion.Cellid, Co., Ltd. has completed a Follow-on Equity Offering in the amount of KRW 23.175 billion. Security Name: Common Stock Security Type: Common Stock Securities Offered: 6,422,072 Price\Range: KRW 3090 Discount Per Security: KRW 49.44 Security Name: Common Stock Security Type: Common Stock Securities Offered: 1,077,928 Price\Range: KRW 3090 Discount Per Security: KRW 49.44 Transaction Features: Rights Offering
New Risk • Jul 23New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of South Korean stocks, typically moving 12% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (12% average weekly change). Earnings have declined by 34% per year over the past 5 years. Revenue is less than US$1m. Minor Risks Shareholders have been diluted in the past year (40% increase in shares outstanding). Market cap is less than US$100m (₩31.1b market cap, or US$22.4m).
New Risk • May 27New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 8.3% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₩18b free cash flow). Earnings have declined by 34% per year over the past 5 years. Revenue is less than US$1m. Minor Risks Share price has been volatile over the past 3 months (8.3% average weekly change). Shareholders have been diluted in the past year (40% increase in shares outstanding). Market cap is less than US$100m (₩39.4b market cap, or US$29.0m).
분석 기사 • Feb 28Is Cellid (KOSDAQ:299660) Using Debt In A Risky Way?Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...
New Risk • Sep 26New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 40% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₩11b free cash flow). Earnings have declined by 44% per year over the past 5 years. Revenue is less than US$1m (₩480m revenue, or US$356k). Minor Risks Share price has been volatile over the past 3 months (10% average weekly change). Shareholders have been diluted in the past year (40% increase in shares outstanding). Market cap is less than US$100m (₩57.6b market cap, or US$42.8m).
New Risk • Jun 20New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 8.2% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₩11b free cash flow). Earnings have declined by 34% per year over the past 5 years. Revenue is less than US$1m (₩480m revenue, or US$373k). Minor Risks Share price has been volatile over the past 3 months (8.2% average weekly change). Market cap is less than US$100m (₩64.2b market cap, or US$49.9m).
Board Change • Nov 16No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 8 experienced directors. No highly experienced directors. No independent directors (8 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.
공시 • Mar 21Cellid, Co., Ltd. announced that it has received KRW 19 billion in fundingOn March 19, 2021, Cellid, Co., Ltd. (KOSDAQ:A299660) closed the transaction.
공시 • Mar 19Cellid, Co., Ltd. announced that it expects to receive KRW 19 billion in fundingCellid, Co., Ltd. (KOSDAQ:A299660) announced a private placement of 2nd series unregistered non-guaranteed private equity convertible bonds for gross proceeds of KRW 19,000,000,000 on March 17, 2021. The transaction will include participation from Daily Bio Health Care 1 Startup Venture Private Equity Joint Venture. The bonds will carry a zero coupon rate and zero yield to maturity. The bonds will mature on March 19, 2026. The bonds will be fully convertible into 515,296 shares of the company at a price of KRW 36,872 per share between the period of March 19, 2022 to February 19, 2026. The transaction has been approved by the board of directors of the company. The expected payment date and subscription date is March 19, 2021.
분석 기사 • Mar 04Is Cellid (KOSDAQ:299660) In A Good Position To Invest In Growth?Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
공시 • Feb 25Cellid, Co., Ltd., Annual General Meeting, Mar 24, 2021Cellid, Co., Ltd., Annual General Meeting, Mar 24, 2021, at 10:00 Korea Standard Time.
Is New 90 Day High Low • Jan 13New 90-day low: ₩37,650The company is down 24% from its price of ₩49,250 on 15 October 2020. The South Korean market is up 29% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is up 23% over the same period.
분석 기사 • Nov 19Cellid (KOSDAQ:299660) Is In A Good Position To Deliver On Growth PlansThere's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...
Is New 90 Day High Low • Oct 05New 90-day high: ₩50,700The company is up 81% from its price of ₩28,050 on 07 July 2020. The South Korean market is up 8.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is up 5.0% over the same period.